| Item type |
[ELS]紀要論文 / Departmental Bulletin Paper(1) |
| 公開日 |
2019-03-27 |
| タイトル |
|
|
タイトル |
The leukotriene receptor antagonist montelukast sodium is effective in patients with recurrent bronchodilator-unresponsive chronic dry cough |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Montelukast sodium |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Leukotriene receptor antagonist |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
β_2-adrenoreceptor agonist |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Atopic cough |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Eosinophilic bronchitis without asthma |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
departmental bulletin paper |
| 雑誌書誌ID |
|
|
収録物識別子タイプ |
NCID |
|
収録物識別子 |
AA11877461 |
| ページ属性 |
|
|
内容記述タイプ |
Other |
|
内容記述 |
P |
| 論文名よみ |
|
|
タイトル |
The leukotriene receptor antagonist montelukast sodium is effective in patients with recurrent bronchodilator-unresponsive chronic dry cough |
| 著者 |
YAMASAKI, Hidetomo
YAMASAKI, Keiko
TANAKA, Toshifumi
YAMASAKI, Hideki
OHSAWA, Nakaaki
|
| 著者所属(英) |
|
|
|
en |
|
|
Yamasaki Clinic : Aino Institute for Aging Research |
| 著者所属(英) |
|
|
|
en |
|
|
Yamasaki Clinic |
| 著者所属(英) |
|
|
|
en |
|
|
Aino Institute for Aging Research |
| 著者所属(英) |
|
|
|
en |
|
|
Yamasaki Clinic |
| 著者所属(英) |
|
|
|
en |
|
|
Aino Institute for Aging Research |
| 記事種別(英) |
|
|
内容記述タイプ |
Other |
|
内容記述 |
Original Paper |
| 抄録(英) |
|
|
内容記述タイプ |
Other |
|
内容記述 |
There have been extremely a few reports regarding the effectiveness of leukotriene receptor antagonist (LTRA) in the treatment of patients with bronchodilatorunresponsive chronic dry cough (BU-CDC). Methods : Research on 12 patients (4 males, 8 females, 9 with atopic factors; age 41±18 yrs) with BU-CDC was carried out to investigate the effects of a 2-week course of the LTRA montelukast sodium (MT) at a dosage of 10 mg once daily. The patients studied had a cough that had persisted for over 4 weeks, which had already failed to be treated with a 2-week course of the β_2-adrenoreceptor agonist. Their response to MT was clinically judged using a cough score (CS). Results: (1) Of the 12 cases studied, 4 cases (33%) showed a good response, 3 (25%) showed a moderate response, and 5 (42%) showed no response. In the total cases, the rate of effectiveness was 58%, and the improvement rate of CS (i-CS) was 28% (P=0.03). (2) The duration of the cough was negatively correlated with the i-CS (r=-0.48, P=0.08), but there was no correlation between the cough severity and the i-CS. (3) Sub-analysis showed that the longer the cough persisted, the poorer the responsiveness was; the i-CS was, 15% in 6 cases with a cough persisting for over 8 weeks, and 40% in 6 cases with a cough persisting for less than 8 weeks (P=0.10). There were no significant differences between the high CS cases and low CS ones, or between the male cases and female ones. Conclusions : MT is effective not only in the treatment of patients with bronchial asthma and cough variant asthma, but also in the treatment of patients with BU-CDC, mostly corresponding to eosinophilic tracheobronchitis with cough hypersensitivity (Fujimura et al) or eosinophilic bronchitis without asthma (Gibson et al). |
| 書誌情報 |
en : Aino journal
巻 3,
発行日 2004
|
| 表示順 |
|
|
内容記述タイプ |
Other |
|
内容記述 |
14 |
| アクセション番号 |
|
|
内容記述タイプ |
Other |
|
内容記述 |
KJ00004291418 |
| ISSN |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
1348480X |
KJ00004291418.pdf (899.1 kB)
